Manage your formulary budget
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
|Title:||HIV protease inhibitors useful for the treatment of AIDS|
|Abstract:||Compounds of formula ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or optionally-substituted C.sub.1-4 alkyl or aryl, or R.sup.1 and R.sup.2 are joined together to form a monocyclic or bicyclic ring system, are HIV protease inhibitors. These compounds are useful in the treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of treating infection by HIV are also described.|
|Inventor(s):||Vacca; Joseph P. (Telford, PA), Dorsey; Bruce D. (Harleysville, PA), Guare; James P. (Quakertown, PA), Holloway; M. Katharine (Lansdale, PA), Hungate; Randall W. (Lansdale, PA), Levin; Rhonda B. (Lafayette Hill, PA)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.